CAD Clinical Trial
— COASTOfficial title:
Coronary Orbital Atherectomy System Study
NCT number | NCT02132611 |
Other study ID # | CLN-0005-P |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2014 |
Est. completion date | June 2017 |
Verified date | July 2023 |
Source | Abbott Medical Devices |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the COAST clinical study data will be to utilize and to gain approval for commercializing the Micro Crown as part of the Coronary Orbital Atherectomy System (OAS).
Status | Completed |
Enrollment | 100 |
Est. completion date | June 2017 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must be 18 or older. - Subjects must have a clinical indication for coronary intervention. - CK and CK-MB must be less than or equal to the upper limit of lab normal value within 8 hours prior to the procedure. - The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure. - The target vessel must be a native coronary artery. - The target vessel reference diameter must be >= 2.5mm and <= 4.0 mm. - The lesion length must not exceed 40 mm. - The target vessel must have a TIMI flow three (3) at baseline. - The target lesion must have fluoroscopic, IVUS or OCT evidence of severe calcium deposit at the lesion site. - The lesion must be crossable with the study guide wire. Exclusion Criteria: - Inability to understand the study requirements or has a history of non-compliance with medical advice. - Unwilling to sign the COAST ICF. - History of any cognitive or mental health status that would interfere with study participation. - Currently enrolled in any other pre-approval investigational study. - Female subjects who are pregnant or planning to become pregnant within the study period. - Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications. - Known sensitivity to contrast media, which cannot be adequately pre-medicated. - Diagnosed with chronic renal failure unless under hemodialysis, or has a serum creatinine level > 2.5 mg/dl. - Experienced acute MI, STEMI or non-STEMI: CK-MB greater than the upper limit of lab normal value, within 30 days prior to index procedure. - History of major cardiac intervention within 30 days. - Evidence of heart failure - History of a stroke or TIA within six (6) months. - Active peptic ulcer or upper GI bleeding within six (6) months. - History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion, if one should become necessary. - Concurrent medical condition with a life expectancy of < 12 months. - History of immune deficiency. - Uncontrolled insulin dependent diabetes. - Evidence of active infections on the day of the index procedure. - Subject has planned cardiovascular intervention within 60 days post index procedure. - Subject is not an acceptable candidate for emergent CABG surgery. - Subject with known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide. - Subject with angiographically confirmed evidence of more than one (1) lesion requiring intervention, unless the treatment of the lesions is staged. - Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass. - Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate or on-line QCA. - Target vessel has angiographically visible or suspected thrombus. - Target vessel has a stent from previous PCI. - Target vessel appears to be or is excessively tortuous at baseline. - Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left main lesion. - Target lesion is a bifurcation. - Target lesion has a = 1.5 mm side branch. - Angiographic evidence of a dissection prior to initiation of OAD. |
Country | Name | City | State |
---|---|---|---|
Japan | Shonan Kamakura General Hospital | Kamakura-city | Kanagawa |
Japan | Kyoto Katsura Hospital | Kyoto | Nishikyo-ku |
Japan | Miyazaki Medical Association Hospital | Miyazaki-city | Miyazaki |
Japan | Sapporo Higashi Tokushukai Hospital | Sapporo-city | Hokkaido |
Japan | Saiseikai Yokohamashi Tobu Hospital | Yokohama-shi | Kanagawa |
United States | Chandler Regional Medical Center and Mercy Gilbert Medical Center | Chandler | Arizona |
United States | Duke University | Durham | North Carolina |
United States | North Florida Regional Medical Center | Gainesville | Florida |
United States | Palm Beach Gardens | Jupiter | Florida |
United States | Columbia University Medical Center | New York | New York |
United States | Mount Sinai Hospital New York | New York | New York |
United States | Munroe Regional Health System, Inc. | Ocala | Florida |
United States | Florida Hospital | Orlando | Florida |
United States | NC Heart and Vascular Research | Raleigh | North Carolina |
United States | St. Francis Hospital | Roslyn | New York |
United States | Baptist Memorial Hospital/Stern Cardiovascular Foundation, Inc. | Southaven | Mississippi |
United States | Tallahassee Research Institute | Tallahassee | Florida |
Lead Sponsor | Collaborator |
---|---|
Abbott Medical Devices |
United States, Japan,
Martinsen BJ, Kumar K, Saito S, Sharma SK, Ikeno F, Fearnot NE, Shlofmitz RA, Thatcher R, Krucoff MW. Japan-USA Orbital Atherectomy for Calcific Coronary Lesions: COAST Study, Harmonization by Doing Proof-of-Concept. Cardiovasc Revasc Med. 2022 Apr;37:112 — View Citation
Redfors B, Sharma SK, Saito S, Kini AS, Lee AC, Moses JW, Ali ZA, Feldman RL, Bhatheja R, Stone GW. Novel Micro Crown Orbital Atherectomy for Severe Lesion Calcification: Coronary Orbital Atherectomy System Study (COAST). Circ Cardiovasc Interv. 2020 Aug; — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major Adverse Cardiac Event (MACE) | A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 30 days.
30-Day MACE is composed of: Cardiac death Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure |
30 Days | |
Secondary | Procedural Success | Procedural success was defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions. | Participants were followed from baseline procedure through the duration of hospital stay, an average of 50.4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04459299 -
CorPath GRX STEMI Study
|
||
Not yet recruiting |
NCT02853994 -
Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
Recruiting |
NCT06239493 -
IVUS-Guided Treatment for Percutaneous Vascular Interventions
|
||
Recruiting |
NCT05344612 -
Comparing a Diagnostic and Treatment Strategy of Upfront CTCA With SOC in Patients With Chest Pain and Suspected CAD
|
N/A | |
Terminated |
NCT03901079 -
Trial for A Novel Facilitated Antegrade Steering Technique in Revascularization of Coronary Chronic Total Occlusions
|
||
Completed |
NCT02457455 -
Urgent Medical and Surgical Conditions During Flights
|
N/A | |
Recruiting |
NCT05509010 -
AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry
|
||
Completed |
NCT03930589 -
Remote Ischemic Conditioning in STEMI to Decrease Infarct Size
|
N/A | |
Completed |
NCT01251302 -
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
|
||
Withdrawn |
NCT02158754 -
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
|
||
Completed |
NCT01949844 -
Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies
|
N/A | |
Recruiting |
NCT04787796 -
The Application of a Portable Multichannel ECG System for the Patients Suspected to Have Possible CAD or ACS
|
N/A | |
Recruiting |
NCT03894423 -
Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
|
||
Completed |
NCT02223286 -
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
|
N/A | |
Completed |
NCT06154018 -
Heparin Reversal With Two Different Protamine Ratios After Cardiopulmonary By-pass.
|
N/A | |
Completed |
NCT01406990 -
Aspirin Responsiveness in Women With Coronary Artery Disease
|
N/A | |
Completed |
NCT01402804 -
NSAIDs in Coronary Artery Disease Patients
|
N/A | |
Completed |
NCT00500617 -
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
|